153 related articles for article (PubMed ID: 25877445)
1. Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes.
Chapron B; Risler L; Phillips B; Collins C; Thummel K; Shen D
J Pharm Pharm Sci; 2015; 18(1):101-11. PubMed ID: 25877445
[TBL] [Abstract][Full Text] [Related]
2. Effect of telaprevir on the metabolism and hepatic uptake of tacrolimus (FK506).
Oda K; Yamano K
Biopharm Drug Dispos; 2014 Dec; 35(9):501-12. PubMed ID: 25059890
[TBL] [Abstract][Full Text] [Related]
3. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
Amundsen R; Åsberg A; Ohm IK; Christensen H
Drug Metab Dispos; 2012 Apr; 40(4):655-61. PubMed ID: 22205779
[TBL] [Abstract][Full Text] [Related]
5. In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure.
Oda K; Yamano K; Otsuka Y
Biopharm Drug Dispos; 2015 Jul; 36(5):265-74. PubMed ID: 25600613
[TBL] [Abstract][Full Text] [Related]
6. Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats.
Zhai J; Zhang F; Gao S; Chen L; Feng G; Yin J; Chen W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28786954
[TBL] [Abstract][Full Text] [Related]
7. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human.
Haarhoff ZE; Kramer MA; Zvyaga TA; Zhang J; Bhutani P; Subramanian M; Rodrigues AD
Xenobiotica; 2017 Jun; 47(6):470-478. PubMed ID: 27498589
[TBL] [Abstract][Full Text] [Related]
9. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
11. In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats.
Saito Y; Nishimura Y; Kurata N; Iwase M; Aoki K; Yasuhara H
J Pharmacol Sci; 2011; 115(3):399-407. PubMed ID: 21358120
[TBL] [Abstract][Full Text] [Related]
12. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin.
Garg V; Chandorkar G; Farmer HF; Smith F; Alves K; van Heeswijk RP
J Clin Pharmacol; 2012 Oct; 52(10):1566-73. PubMed ID: 22162542
[TBL] [Abstract][Full Text] [Related]
13. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CYP3A by Antimalarial Piperaquine and Its Metabolites in Human Liver Microsomes With IVIV Extrapolation.
Aziz MY; Hoffmann KJ; Ashton M
J Pharm Sci; 2018 May; 107(5):1461-1467. PubMed ID: 29352982
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.
Mao J; Tay S; Khojasteh CS; Chen Y; Hop CE; Kenny JR
Pharm Res; 2016 May; 33(5):1204-19. PubMed ID: 26869174
[TBL] [Abstract][Full Text] [Related]
16. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
[TBL] [Abstract][Full Text] [Related]
18. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of schisandrin A and schisandrin B on CYP3A activity.
Li WL; Xin HW; Su MW; Xiong L
Methods Find Exp Clin Pharmacol; 2010 Apr; 32(3):163-9. PubMed ID: 20448858
[TBL] [Abstract][Full Text] [Related]
20. Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients.
Emoto C; Vinks AA; Fukuda T
Ther Drug Monit; 2016 Oct; 38(5):607-13. PubMed ID: 27310200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
